For nearly two decades, Amgen, a global leader in the pharmaceutical industry, has leaned into the development of innovative personalized medicines that promise big benefits for relatively small patient populations. Executive Vice President David Reese discusses the future of the company and the field.

MODERATOR | Clifton Leaf, former Editor-in-Chief, Fortune magazine

KEYNOTE SPEAKER | David Reese, M.D., Executive Vice President, Chief Technology Officer, Amgen

Illumina, a $23 billion genomic sequencing technology company, has broad-based ambitions for personalized medicine to transform health care across multiple fronts. CEO Jacob Thaysen reveals his vision for the future.

MODERATOR | Clifton Leaf, former Editor-in-Chief, Fortune magazine

KEYNOTE SPEAKER | Jacob Thaysen, Ph.D., CEO, Illumina

Personalized medicine depends on a strong diagnostics industry, which faces an uncertain future. This panel examines the perspectives of investors and senior executives on the financial future of the industry.

MODERATOR | Michael D. Goldberg, Executive Chairman, DNAnexus, Chairman, CareDx

Brian Caveney, M.D., Chief Medical & Scientific Officer, Labcorp

Michael Pellini, M.D., General Partner, S32

Sam Raha, Chief Operating Officer, Myriad Genetics

Matthew Sykes, Managing Director, Life Sciences and Diagnostics Industry Investments, Goldman Sachs

The Annual Award for Leadership in Personalized Medicine recognizes an individual whose contributions in science, business, and policy have helped advance the frontiers of the field.

PRESENTER | Brian Munroe, Founder, Board Member, Personalized Medicine Coalition

AWARDEE | Emily Kramer-Golinkoff, Co-Founder, Emily’s Entourage

MODERATOR | Ángel Alberich-Bayarri, Ph.D., Founder, CEO, Quibim (session sponsor)

Chiranjiv Singh, Vice President & General Manager, Pixel at Tempus AI

Okan Ekinci, M.D., Chief Medical Information Officer, Roche Information Solutions

Megan Nacar, Vice President of Commercial, DeciBio

Christi Shaw has served as the CEO of a pioneering biopharmaceutical company, as a board member for several life sciences companies, and as a co-founder of the More Moments More Memories Foundation. She also spent a year as a full-time caregiver to her sister. Ms. Shaw reflects on three decades of service to the health care community.

MODERATOR | Kathy Bloomgarden, CEO, Ruder Finn

SPEAKER | Christi Shaw, former CEO, Kite Pharma

All countries benefit from the advancement of personalized medicine. National leaders reflect on shared challenges and opportunities.

MODERATOR | Antonio Andreu, M.D., Ph.D., Scientific Director, European Infrastructure for Translational Medicine

Joshua C. Denny, M.D., CEO, All of Us Research Program, U.S. National Institutes of Health

Monika Frenzel, Ph.D., Research Funding and Support Leader, European Partnership for Personalised Medicine; International Coordinator, French National Research Agency

By detecting molecular cancer signals in the bloodstreams of seemingly healthy patients, a new generation of minimally invasive early cancer detection tests promises to put more patients on the path to personalized cancer treatment, sooner. What might this mean for the future of cancer care? Leading voices discuss.

MODERATOR | Felice Freyer, President, Association of Health Care Journalists

Christina Annunziata, M.D., Ph.D., Senior Vice President, Extramural Discovery Science, American Cancer Society

Tomasz Beer, M.D., Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences

Bruce Ratner, Author, Early Detection: Catching Cancer When It’s Curable

Sapna Syngal, M.D., M.P.H., Director of Strategic Planning for Prevention and Early Cancer Detection, Dana-Farber Cancer Institute

The era of personalized medicine has brought breakthrough advancements in areas like genomic sequencing and gene therapy. Will this reshape the futures of pediatric patients with rare genetic diseases? Leading voices discuss opportunities and challenges.

MODERATOR | Paul Billings, M.D., Ph.D., Board Member, Xzom

Lillian Garvin, Operations Lead, Center of Precision Medicine, Nicklaus Children’s Hospital

Mira Irons, M.D., Associate Chief, Genetics and Genomics, Boston Children’s Hospital

Julia Vitarello, Mila’s mom, Founder, CEO, Mila’s Miracle Foundation

Artificial intelligence technologies can query the divergent effects of preventive and treatment interventions across a previously unimaginable range of data points. What might this mean for the future of personalized medicine? Leading voices share visions.

CHAIRPERSON | Joe Franklin, Ph.D., J.D., Special Counsel, Covington & Burling LLP

Ángel Alberich-Bayarri, Ph.D., Founder, CEO, Quibim

Okan Ekinci, M.D., Chief Medical Information Officer, Roche Information Solutions

John Ellithorpe, Ph.D., President, DNAnexus

Jonathan Kish, Ph.D., Head of Research Sciences, Flatiron Health

Kate Sasser, Ph.D., Chief Scientific Officer, Tempus

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

Museum of Fine Arts
465 Huntington Avenue
Boston, MA 02115

As the Chief Medical Officer of the pharmaceutical industry’s leading trade association, Michael Ybarra, an emergency medicine physician, is helping industry executives shape and navigate shifting scientific, economic, and political landscapes in Washington and around the world. Dr. Ybarra shares the pharmaceutical industry’s point-of-view on the status and future of personalized medicine in light of recent public policy changes in the United States.

INTRODUCTION | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

KEYNOTE SPEAKER | Michael Ybarra, M.D., Chief Medical Officer, PhRMA

GRAIL and Point32Health are evaluating the impact of blood-based screening tests used to detect cancers before they cause symptoms in a real-world health plan setting. Partner executives reflect on the findings to date.

MODERATOR | Felice Freyer, President, Association of Health Care Journalists

Joshua Ofman, M.D., President, GRAIL

Kate Wallis, Vice President, Clinical Innovation, Point32Health

For clinical care providers, personalized medicine may present opportunities to improve care for their patients and make better use of scarce resources by targeting treatments to those most likely to benefit from them. But spearheading the clinical adoption of personalized medicine is anything but easy. Representatives from leading clinical institutions reflect on opportunities and challenges.

MODERATOR | Susanne Munksted, Chief Precision Medicine Officer, Diaceutics

Justin Brueck, System Vice President, Innovation and Research, Endeavor Health

Manoja Lecamwasam, Ph.D., System Vice President, Intellectual Property, Strategic Life Sciences and Device Innovation, CommonSpirit Health

Apostolia M. Tsimberidou, M.D., Ph.D., Professor, Department of Investigational Therapeutics, The University of Texas MD Anderson Cancer Center

Daryl Pritchard, who serves as the Senior Vice President for Science Policy at the Personalized Medicine Coalition, introduces the Coalition’s new Roadmap for Addressing Clinical Practice Gaps in Precision Cancer Care.

SPEAKER | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition

After the first sequencing of a human genome in 2003, officials from the U.S. National Institutes of Health introduced personalized medicine as a “newly created discipline” that promised to “make a profound difference to the health and well-being of all the people of this world.” Pioneering leaders reflect on the past, present, and future of this promise.

MODERATOR | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

Mark Levin, Partner, Third Rock Ventures

Ralph Snyderman, M.D., Chancellor Emeritus, Duke University

Janet Woodcock, M.D., former Acting Commissioner, U.S. Food and Drug Administration